Drugs / Guadecitabine
Guadecitabine
also known as
SGI-110 · Guadecitabina · guadecitabine (SGI-110) · GUADECITABINE SODIUM · S110 sodium salt · Sgi-110 free acid · SGI-110 sodium salt
Trials 33 · a red edge is where a trial was stopped
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-10-15 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML otsuka.co.jp ↗ |
| 2018-07-31 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy otsuka.co.jp ↗ |
| 2016-04-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia otsuka.co.jp ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guadecitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02907359 ↗ |
| Known as | Guadecitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544916 ↗ |
| Known as | guadecitabine (SGI-110) | “guadecitabine (SGI-110)” NCT04250246 ↗ |
| Known as | GUADECITABINE SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544916 ↗ |
| Known as | S110 sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544916 ↗ |
| Known as | SGI-110 | “A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and...” NCT03257761 ↗14“Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of Decitabine and deoxyguanosine resistant to degradation by cytidine deaminase.” NCT03454984 ↗ “Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors” NCT02429466 ↗ “Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent” NCT02998567 ↗ “SGI-110 (guadecitabine)” NCT02348489 ↗ |
| Known as | Sgi-110 free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544916 ↗ |
| Known as | SGI-110 sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544916 ↗ |
| Action | Inhibit | “Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor” PMID 31331399 ↗ Jul 2019 |
| Modality | Oligonucleotide (other) | “Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase.” PMID 26296954 ↗ Aug 2015 |
| Route | Subcutaneous | “subcutaneously given guadecitabine” PMID 26296954 ↗ Aug 2015 |